The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors

Canadian Journal of Cardiology

Volumn 15, Issue 4, 1999, Pages 419-427

  Connelly, Philip W ^a,d   Stachenko, Sylvie ^b   MacLean, David R ^c   Petrasovits, Andres ^b   Little, J Alick ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b HEALTH CANADA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d J Alick Little Lipid Res Laboratory   (Canada)

Author keywords

Cholesterol; Coronary disease; Hormones; Lipids; Lipoproteins; Population health; Triglycerides; Women

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; SEX HORMONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CANADA; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; ORAL CONTRACEPTION; PREVALENCE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CANADA; CONTRACEPTIVES, ORAL; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEINS; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION;

EID: 0032937018     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. The Lipid Research Clinics Program Epidemiology Committee. Circulation 1979;60:427-39.
2. Wallace RB, Hoover J, Barrett-Connor E, et al. Altered plasma lipid and lipoprotein levels associated with oral contraceptive and oestrogen use. Report from the Medications Working Group of the Lipid Research Clinics Program. Lancet 1979;ii:112-5.
3. Campos H, Wilson PW, Jimenez D, McNamara JR, Ordovas J, Schaefer EJ. Differences in apolipoproteins and low-density lipoprotein subfractions in postmenopausal women on and off estrogen therapy: results from the Framingham Offspring Study. Metabolism 1990;39:1033-8.
4. Knopp RH, Zhu X, Bonet B. Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women. Atherosclerosis 1994;110(Suppl):S83-91.
5. Sacks FM, Walsh BW. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol 1994;5:236-40.
6. Vaziri SM, Evans JC, Larson MC, Wilson PW. The impact of female hormone usage on the lipid profile. The Framingham Offspring Study. Arch Intern Med 1993;153:2200-6.
7. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-204.
8. Sacks FM, Gerhard M, Walsh BW. Sex hormones, lipoproteins, and vascular reactivity. Curr Opin Lipidol 1995;6:161-6.
9. Walsh BW, Sacks FM. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism. J Clin Invest 1993;91:2126-32.
10. Spitzer WO. Data from transnational study of oral contraceptives have been misused. BMJ 1995;311:1162. (Lett)
11. Lewis MA, Spitzer WO, Heinemann LA, MacRae KD, Bruppacher R, Thorogood M. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996;312:88-90.
12. Health Protection Branch, Health Canada. Directions For Use of Estrogen-Progestin Combination Oral Contraceptives. Drugs Directorate Guidelines [Cat No H42-2/60-1994]. Ottawa: Canadian Government Publishing Centre, Supply and Services Canada, 1994.
13. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210.
14. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-62.
15. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1775.
16. Bush TL. Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J 1996;17(Suppl D):9-14.
17. Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation 1997;95:252-64.
18. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
19. Nathan L, Chaudhuri G. Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol 1997;37:477-515.
20. White CR, Darley-Usmar V, Oparil S. Gender and cardiovascular disease - recent insights. Trends Cardiovasc Med 1997;7:94-100.
21. MacLean DR, Petrasovits A, Nargundkar M, et al. Canadian heart health surveys: a profile of cardiovascular risk. Survey methods and data analysis. Canadian Heart Health Surveys Research Group. Can Med Assoc J 1992;146:1969-74.
22. Connelly PW, MacLean DR, Horlick L, O'Connor B, Petrasovits A, Little JA. Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults. Canadian Heart Health Surveys Research Group. Can Med Assoc J 1992;146:1977-87.
23. MacLean DR, Petrasovits A, Connelly PW, Joffres M, O'Connor B, Little JA. Plasma lipids and lipoprotein reference values and the prevalence of dyslipoproteinemia in Canadian adults. Can J Cardiol 1999;15:434-44.
24. Skinner CJ, Holt D, Smith TMF. Analysis of Complex Surveys. West Sussex: John Wiley and Sons, 1989.
25. Thomas DR. Inference using complex data from surveys and experiments. Can Psychol 1993;34:415-31.
26. Wolter K. Introduction to Variance Estimation. New York: Springer-Verlag, 1985:153-200.
27. Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
28. Krauss RM, Perlman JA, Ray R, Petitti DB. Effects of estrogen dose and smoking on lipid and lipoprotein levels in postmenopausal women. Am J Obstet Gynecol 1988;158:1606-11.
29. Granfone A, Campos H, McNamara JR, et al. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in post-menopausal, dyslipidemic women. Metabolism 1992;41:1193-8.
30. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996;143:971-8.
31. Brinton LA, Shairer C. Postmenopausal hormone-replacement therapy - time for a reappraisal? N Engl J Med 1997;336:1821-2.
32. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
33. Petitti DB. Hormone replacement therapy and heart disease prevention. JAMA 1998;280:650-2.